Veligrotug

Enspryng is now approved for use by US patients in two autoimmune indications. Credit: Khan Vector Co / Shutterstock.com. The US Food and Drug Administration (FDA) has granted Roche a label expansion for its ophthalmology therapy, Enspryng (satralizumab), in thyroid eye disease (TED), with the benefit of an at-home administration. This means that the interleukin 6 (IL-6) inhibitor is now greenlit for use in adults with TED – a condition where the body’s own cells attack the muscles, tear glands and connective tissues behind the eyes. Following its label expansion, healthcare providers can now prescribe Enspryng to either be self- or caregiver-administered once every four weeks during the maintenance phase of treatment. Currently, researchers estimate that TED, which is otherwise known as Graves’ ophthalmopathy, impacts around 155 to 250 people per 100,000 globally. The FDA gave Enspryng the TED green light based on the totality of data from the drug’s Phase III SatraGO programme (NCT05987423; NCT06106828). While the drug did not meet its pre-specified primary endpoints in SatraGO-1, patients with both active and chronic TED experienced significant improvements in both double vision and the degree to which their eyeballs bulge. Analysts question commercial impact of Enspryng’s TED market debut Enspryng’s newfound approval expands the drug’s role from its original US approval in neuromyelitis optica spectrum disorder (NMOSD), which came back in 2020. It also makes it the first drug to get the FDA’s blessing as a subcutaneous treatment option in TED, as marketed options , Amgen’s Tepezza (teprotumumab-trbw) and Viridian Therapeutics’ recently greenlit therapy, Lumvoa (veligrotug-vvze), are intravenously administered. However, William Blair analysts note that, despite Enspryng’s place as a first-in-class, subcutaneous addition to the TED treatment paradigm, they do not view the drug as a “major competitive threat” to the anti-IGF-1R class – including drugs like Tepezza and Lumvoa. “We have seen limited excitement for the anti-IL-6 mechanism among doctors. The anti-IGF-1R class is still seen as the gold standard for treating TED, and the data from the SatraGO studies simply does not look particularly competitive,” they added. Though the analysts point to the importance of subcutaneous options in expanding the TED market, they do not believe that the current data will allow the IL-6 drug class to “supplant anti-IGF-1R therapies as the standard of care for a majority of patients”. There are currently several drugs in mid-to-late-stage development for TED, including Novartis-owned Tourmaline Bio’s rival anti-IL-6 therapy, pacibekitug, as well as Sling Therapeutics’ dual ATP-competitive kinase inhibitor pill, linsitinib . Currently, analysts at GlobalData, the parent company of Pharmaceutical Technology, estimate that Enspryng will generate $825m in sales in 2032.

Some six years after scoring an initial FDA nod in neuromyelitis optica spectrum disorder, Roche’s IL-6 receptor inhibitor Enspryng is muscling up to Amgen's Tepezza in a key eye disease arena. The FDA late this week endorsed Enspryng, also known as satralizumab, as a new treatment option for adults living with thyroid eye disease (TED), an autoimmune condition that can lead to swelling and bulging of the eyes, vision problems and pain. The drug is delivered via below-the-skin injection, which can be done by the patient themselves or a caregiver from the comfort of home, according to an Oct. 16 release from Roche’s Genentech unit. A rare condition, TED is estimated to affect roughly 155 out of every 100,000 people in the United States, introducing the risk of facial disfigurement and potential vision-complications if left untreated, Roche said. Beyond the steroids used to control swelling in TED patients, the current treatment landscape is dominated by Amgen’s IGF-1R inhibitor Tepezza—which generated $1.9 billion in 2025 sales—while Viridian Therapeutics just snared a green light for its own TED challenger in similarly classed Lumvoa back in June. Bringing a new mechanism to the table, meanwhile, Enspryng was formulated to bind both soluble and membrane-bound interleukin-6 receptors, in turn inhibiting the IL-6 mediated signaling that Roche has flagged as a key inflammation pathway. The drug’s original 2020 nod in neuromyelitis optica spectrum disorder (NMSOD)—a rare and potentially devastating autoimmune condition that can cause blindness, paralysis and nerve pain—was a first for the IL-6 receptor inhibitor class as well. Roche relied on results from its phase 3 SatraGO program to secure the new TED approval, though Enspryng’s performance across the pair of trials involved was somewhat mixed, with the SatraGO-1 study failing to meet its pre-specified primary efficacy endpoint at the 24-week mark. The drug fared better in SatraGO-2, in which 52.9% of patients who got Enspryng achieved a significant and clinically meaningful difference in proptosis response—referring to the bulging of one or both eyes—compared to 23.4% of those who received placebo. For the reduction of diplopia, or double vision, in SatraGo-2, Enspryng helped chart meaningful improvements in over 60% of patients, versus a score of 25.8% in the trial’s control arm. Those results drew from the study’s active TED population, with Roche noting in its release that the readout in the overall population, which included both active and chronic patients, was “consistent.” “Today’s FDA approval of Enspryng provides an important new option for people with thyroid eye disease, who have long faced limited treatment choices,” said Levi Garraway, M.D., Ph.D., Roche’s chief medical officer and product development chief, in a statement. Apart from bringing a new mechanism of action to bear, Enspryng’s self-injection option could carry a serious convenience edge over Tepezza and Lumvoa, both of which are given via infusion. With Viridian’s Lumvoa approval earlier this summer, the company highlighted the fact that its approval applied to adults with active or chronic TED, making it the first IGF-1R inhibitor cleared in both forms of the disease—a potential advantage over Tepezza. The company also spotlighted the shorter infusion time on Lumvoa—at 30 to 40 minutes versus around an hour on Tepezza—plus a shorter overall treatment period of 12 weeks, too. Meanwhile, adherence and convenience appeared top of mind at the FDA this week, as the U.S. regulator also handed down an approval for a new autoinjector format of UCB’s C5 inhibitor for generalized myasthenia gravis (gMG), Zilbrysq. As in the case of Enspryng, UCB’s subcutaneous Zilbrysq formulation can be received beyond the confines of the doctor’s office or infusion clinic. The new nod marks the second for a self-administration option for Zilbrysq, which was first approved by the FDA for gMG in Oct. 2023, and which also comes in the form of a pre-filled syringe that can be used on one’s own. UCB says it expects to launch its autoinjector in 2027’s first quarter. With the thumbs up, UCB figures it now has the answer to “a question on which we've been relentlessly focused: How do we continue to improve an already effective therapy for daily use?" said Kimberly Moran, Ph.D., SVP and head of rare diseases for the U.S. at UCB, in a statement.